Q1FY27 results: standalone PAT jumps to Rs 65 cr on strong revenue growth

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults RestatedResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+12.1%Reaction day

₹648.50

prior close

₹664.40

announcement price

In-mkt

timing

Nifty Microcap 250market+1.3%+10.8% vs market

Pharmaceuticals peers, median of 165sector-0.0%+12.1% vs sector

On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 12.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+4.6

15m

+4.9

30m

+9.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+12.1+1.3+10.8-0.0+12.1

Next day

+13.7+1.6+12.1+0.1+13.6

+16.9+1.7+15.2+0.3+16.5

+24.6+1.6+23.0+1.0+23.6

+26.5+1.5+25.1+1.2+25.4

+23.8+1.8+22.0+1.0+22.9

+27.0+2.1+24.9+0.5+26.5

15d

+33.2+3.2+30.0-0.0+33.2

+45.0+3.7+41.3+1.7+43.3

+58.8+1.1+57.6+1.0+57.8

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1FY27 standalone net sales rose 104 percent YoY to Rs 165.92 cr; consolidated up 47 percent to Rs 390 cr. Standalone PAT jumped to Rs 64.92 cr from Rs 18.71 cr; consolidated PAT to Rs 100.88 cr from Rs 46.88 cr. Big boost from one-time deferred tax reversal of Rs 26.84 cr. Board set final dividend record date Sept 4; AGM on Sept 11.

Likely market impact

Strong quarter with revenue and PAT well above last year; one-time tax reversal boosted PAT. Watch for sustainability of growth.